Overview

Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease

Status:
Completed
Trial end date:
2018-12-20
Target enrollment:
Participant gender:
Summary
Bone marrow MSCs will be isolated from allogenic donors, expanded under hypoxic conditions using medium containing no serum or animal-derived reagents, and applies for Phase Ⅰ/Ⅱ study in treating 18 recipients with ischemic limb diseases.
Phase:
Phase 1
Details
Lead Sponsor:
Taiwan Bio Therapeutics Co., Ltd.